Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Total Debt (2020 - 2025)

Universe Pharmaceuticals' Total Debt history spans 6 years, with the latest figure at $2.1 billion for Q3 2025.

  • On a quarterly basis, Total Debt fell 73.64% to $2.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 billion, a 73.64% decrease, with the full-year FY2025 number at $2.1 billion, down 73.64% from a year prior.
  • Total Debt hit $2.1 billion in Q3 2025 for Universe Pharmaceuticals, down from $8.0 billion in the prior quarter.
  • Over the last five years, Total Debt for UPC hit a ceiling of $8.0 billion in Q3 2024 and a floor of $7293.0 in Q1 2022.
  • Historically, Total Debt has averaged $1.3 billion across 5 years, with a median of $5.5 million in 2023.
  • Biggest five-year swings in Total Debt: crashed 100.0% in 2021 and later surged 145713.96% in 2024.
  • Tracing UPC's Total Debt over 5 years: stood at $19723.0 in 2021, then surged by 17033.62% to $3.4 million in 2022, then skyrocketed by 62.24% to $5.5 million in 2023, then surged by 145713.96% to $8.0 billion in 2024, then tumbled by 73.64% to $2.1 billion in 2025.
  • Business Quant data shows Total Debt for UPC at $2.1 billion in Q3 2025, $8.0 billion in Q3 2024, and $7.6 million in Q1 2024.